OPPORTUNITIES FOR HIGH-COST DRUGS IN INDIA

被引：0
|
作者：
Ramabadran, A. [1 ]
Samuel, J. J. [2 ]
Edathodu, A. [2 ]
Mukku, S. R. [2 ]
机构：
[1] Univ Cambridge, Cambridge, England
[2] Access Infin Ltd, London, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN240
引用
收藏
页码：A131 / A131
页数：1
相关论文
共 50 条
  • [11] PREDICTED VERSUS ACTUAL BUDGET IMPACT OF HIGH-COST DRUGS IN IRELAND
    Fogarty, E.
    Barry, M.
    VALUE IN HEALTH, 2014, 17 (07) : A426 - A427
  • [12] High-Cost Drugs Account for Most of Medicare Part B Spending
    Mitka, Mike
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (06): : 572 - 572
  • [13] Communication about high-cost drugs in oncology-the patient view
    Kaser, E.
    Shaw, J.
    Marven, M.
    Swinburne, L.
    Boyle, F.
    ANNALS OF ONCOLOGY, 2010, 21 (09) : 1910 - 1914
  • [14] Prioritization of high-cost new drugs for HCV: making sustainability ethical
    Craxi, L.
    Sacchini, D.
    Refolo, P.
    Minacori, R.
    Daloiso, V.
    Ricci, G.
    Bruno, R.
    Camma, C.
    Cicchetti, A.
    Gasbarrini, A.
    Spagnolo, A. G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (06) : 1044 - 1051
  • [15] Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications
    Socal, Mariana P.
    Cordeiro, Thomas
    Anderson, Gerard F.
    Bai, Ge
    JAMA NETWORK OPEN, 2022, 5 (11) : E2239868
  • [16] ASSESSMENT OF PATIENT SATISFACTION WITH PUBLIC PHARMACIES DISPENSING HIGH-COST DRUGS IN GREECE
    Georgi, C.
    Georgis, V
    Karakolias, S.
    VALUE IN HEALTH, 2023, 26 (12) : S308 - S309
  • [17] Senator Urges VA to "Break" Patents for High-Cost Hepatitis C Drugs
    Buchholz, Laura
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02): : 115 - 115
  • [18] A clinical audit of high-cost approved drugs in dermatology: 2003-2013
    Ong, N.
    McMeniman, E.
    Soyer, H. P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 58 - 59
  • [19] Access to high-cost drugs for rare diseases in Brazil: mucopolysaccharidosis Type I
    Boy, R.
    Krug, B.
    Gialdi, O.
    Santana-da-Silva, L. C.
    Steiner, C.
    Acosta, A. X.
    Ribeiro, E. M.
    Galera, M. F.
    Leivas, P. G. C.
    Braz, M.
    Schwartz, I. V.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 : S69 - S69
  • [20] Serious adverse events with high-cost drugs accessed through litigation in Brazil
    da Silva, Ricardo Eccard
    Lima, Elisangela da Costa
    Novaes, Maria Rita C. G.
    Serpa Osorio-de-Castro, Claudia Garcia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 159 - 159
12345